OTC · Medical - Diagnostics & Research

Genetic Technologies Limited (GNTLF) Stock

$1.00 +0.00% OTC: GNTLF Healthcare

Genetic Technologies Limited, trading as GNTLF, is an Australian molecular diagnostics enterprise dedicated to creating and delivering advanced predictive assessment instruments. These tools are designed to assist medical professionals in Australia and the United States with managing women's health.

Valuation

MetricValue
Price$1.00
Market Cap$1.34B
P/E Ratio-0.43
P/B Ratio2.95
P/S Ratio0.74
EPS (TTM)$-0.09
52-Week High$1.00
52-Week Low$1.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-184.98%
ROA-194.25%
ROCE-613.25%
Gross Margin50.94%
Operating Margin-159.30%
Net Margin-156.78%
Debt/Equity0.48
Current Ratio0.88

Annual Financials (USD)

Metric20202021202220232024
Revenue$1.0M$1.0M$9.0M$10.0M$10.0M
Operating Profit$-6.0M$-6.0M$-5.0M$-6.0M$-12.0M
Net Profit$-6.0M$-7.0M$-7.0M$-12.0M$-12.0M
EPS$-0.15$-0.08$-0.08$-0.12$-0.09
Op Margin-708.8%-434.5%-52.2%-58.6%-126.2%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$16.0M$23.0M$21.0M$15.0M$6.0M
Total Liabilities$2.0M$1.0M$4.0M$4.0M$4.0M
Cash$14.0M$21.0M$12.0M$8.0M$1.0M
Borrowings$0$0$1.0M$1.0M$1.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-6.0M$-6.0M$-6.0M$-10.0M$-10.0M
Investing Cash Flow$0$-1.0M$-4.0M$0$0
Financing Cash Flow$-3.0M$-2.0M$0$-1.0M$0
Net Cash Flow$12.0M$7.0M$-9.0M$-4.0M$-7.0M
Free Cash Flow$-6.0M$-7.0M$-6.0M$-10.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.48
FCF Yield-171.25%
Quick Ratio0.83
Interest Coverage-236.53
Return 1Y0.00%
Return 3Y566.67%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CHIZFChina Traditional Chinese Medicine Holdings Co. Limited $0.16 +0.00% -19.84 $821.34M 6.25%
CMOPFCosmo Pharmaceuticals N.V. $77.13 +2.66% -298.59 $1.32B 3.19%
CSPHFCStone Pharmaceuticals $0.71 +0.00% -19.48 $1.14B 0.00%
EVOTFEvotec SE $6.69 +0.00% -3.18 $1.19B 0.00%
MRCHFH.U. Group Holdings, Inc. $20.05 +1.78% 28.31 $1.11B 3.84%

About Genetic Technologies Limited

Genetic Technologies Limited, trading as GNTLF, is an Australian molecular diagnostics enterprise dedicated to creating and delivering advanced predictive assessment instruments. These tools are designed to assist medical professionals in Australia and the United States with managing women's health. The company's primary offering is BREVAGenplus, a meticulously validated risk evaluation test specifically for non-inherited breast cancer. Genetic Technologies promotes BREVAGenplus to a wide array of healthcare specialists, including those working in breast health clinics and imaging centers, obstetricians/gynecologists, and experts in breast cancer risk analysis, such as breast surgeons. Beyond this flagship product, the firm provides additional cancer risk assessment tests under the GeneType brand, specifically for Colorectal Cancer and Breast Cancer. It also has ongoing development efforts for new risk assessment diagnostics targeting various conditions, including cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma. Furthermore, the company offers a comprehensive suite of genetic testing services encompassing medical, animal, forensic, and botanical applications. Established in 1987 and headquartered in Fitzroy, Australia, Genetic Technologies Limited actively engages in research and collaborative ventures with prominent institutions such as the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom.

Genetic Technologies Limited is headquartered in AU.

Genetic Technologies Limited (GNTLF) stock trades at $1.00 with a market capitalization of $1.34B. The stock is valued at a price-to-earnings (P/E) ratio of -0.43, price-to-book of 2.95, price-to-sales of 0.74. Over the past 52 weeks the stock has ranged between $1.00 and $1.00, and currently trades at its 52-week high.

On profitability, Genetic Technologies Limited generates a return on equity (ROE) of -184.98%, return on capital employed of -613.25%, an operating margin of -159.30%, a net profit margin of -156.78%.

Official website: genetype.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides